Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Chemotherapy for Uterine Carcinosarcoma

Comparing clinical outcomes

Adjuvant chemotherapy and chemo-radiation were associated with improved survival in 10,609 patients diagnosed with uterine carcinosarcoma with overall rates of chemotherapy increasing over time. Most patients underwent definitive surgery, and lymphadenectomy was performed in 68.7% of the patients. Chemotherapy was administered in 22.4% of patients; radiotherapy in 20.7% of patients, adjuvant chemotherapy in 17% of patients, and 40% of women did not received adjuvant therapy. Researchers found:

• The lowest hazard ratio observed was in patients that received chemo-radiation.

• The strongest quantitative predictor of death was state at the time of diagnosis.

• Surgical treatment, lymph node dissection, most recent time-periods, lower comorbidity index, and higher socioeconomic status were associated with improved survival.

Citation: Alejandro Rauh-Hain J, Starbuck KD, Meyer LA, et al. Patterns of care, predictors and outcomes of chemotherapy for uterine carcinosarcoma: A national cancer database analysis. Gynecol Oncol. [Published online ahead of print August 22, 2015]. doi: 10.1016/j.ygyno.2015.08.014.